



# EV 2 961689 US

ORM HDP-1449 (Based on Form PTO-1449)

## PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET NO.	SERIAL NO.
6794S-000019/US	09/897,801
APPLICANT	
Pinkerton, Thomas C.	
FILING DATE	GROUP
June 29, 2001	1615

#### Express Mail No. EV 262961689 US

U.S. P	ATENT DO	CUMENTS				
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.	1	5,983,130	11/09/1999	Phipps et al.	604/20	

FORE	IGN PATEN	IT DOCUMENTS		:,	<u> </u>	
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes
2.	CAR	WO 02/02178	01/10/2002	PCTWIPO	A61M-37/00	
3.		WO 02/02179	01/10/2002	PETWIPD	<del>A61M-37/0</del> 0	
4.		WO 01/13989	03/01/2001	PGF WIPD	<del>'A61N 1/32'</del>	
5.		WO 99/64580	12/16/1999	PETWIPO	<del>C12N 15/00</del>	
6.		WO 99/58188	11/18/1999	PCI WIPD	- <del>A61N-1/00</del>	

OTHER	DOCUMEN	NTS (including Author, Title, Date, Pertinent Pages, et	c.)
1	Examiner's nitials		
7.	as	PCT, International Searching Authority; 5/11/2002	
	<b>\</b> J		TOX OR

Examiner:

Date Considered:

/16/03

### PATENT AND TRADEMARK OFFICE O 1 PINFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

(Use several sheets if necessary)

Sheet 1 of 6

ATTORNEY DOCKET No.	SERIAL NO.
6794S-000019/US	09/897,801
APPLICANT	
Pinkerton, Thomas C.	
FILING DATE	GROUP
June 29, 2001	1615

U.S. P	U.S. PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date		
1.	CA	2,619,962	12/02/1952	Rosenthal	128/253			
2.	1	3,814,097	06/04/1974	Ganderton, et al.	128/268			
3.		3,964,482	06/22/1976	Gerstel, et al.	128/260			
4.		4,270,537	06/02/1981	Romaine	128/218 A			
5.		4,592,753	06/03/1986	Panoz	604/897			
6.		4,886,499	12/12/1989	Cirelli, et al.	604/131			
7.		5,003,987	04/02/1991	Grinwald	128/734			
8.		5,098,389	03/24/1992	Cappucci	604/158			
9.		5,156,591	10/20/1992	Gross, et al.	604/20			
10.		5,250,023	10/05/1993	Hai Bang Lee, et al.	604/20			
11.		5,279,544	01/18/1994	Gross, et al.	604/20			
12.		5,279,552	01/18/1994	Magnet	604/47			
13.		5,417,662	05/23/1995	Hjertman, et al.	604/117			
14.		5,527,288	06/18/1996	Gross, et al.	604/140			
15.		5,582,591	12/10/1996	Cheikh	604/51			
16.		5,591,139	01/07/1997	Lin, et al.	604/264			
17.		5,801,057	09/01/1998	Smart, et al	436/68			
18.		5,820,622	10/13/1998	Gross, et al.	604/890.1			
19.		5,848,990	12/15/1998	Cirelli, et al.	604/136			
20.		5,848,991	12/15/1998	Gross, et al.	604/140			
21.	18	5,876,582	03/02/1999	Frazier	205/122			

Examiner:

Date Considered:

## PATENT AND TRADEMARK OFFICE MEFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 2 of 6

ATTORNEY DOCKET No.	SERIAL NO.		
6794S-000019/US	09/897,801		
APPLICANT			
Pinkerton, Thomas C.			
FILING DATE	GROUP		
June 29, 2001	1615		

U.S. P	U.S. PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date		
22.	(AX	5,879,326	03/09/1999	Godshall, et al.	604/51			
23.		5,928,207	07/27/1999	Pisano, et al.	604/272			
24.		5,957,895	09/28/1999	Sage, et al.	604/181			
25.		5,997,501	12/07/1999	Gross, et al.	604/65	·		
26.		6,056,716	05/02/2000	D'Antonio, et al.	604/68			
27.		6,099,504	08/08/2000	Gross, et al.	604/140			
28.		6,319,224 B1	11/20/2001	Stout, et al.	604/68			
29.		6,334,856 B1	01/01/2002	Allen, et al.	604/191			
30.	CAS	6,346,095 B1	02/12/2002	Gross, et al.	604/272			
31.	CA	09/606909		Pettis, et al.	604/28	06/29/2000		

FORE	IGN PATEN	IT DOCUMENTS			-		
Ref. Desig.	Examiner's	Document Number	Date	Country	Class/ Subclass	Translatior Yes	n No
32.		CA 2,349,431	05/25/2000	Canada	A61K-39/00		
33.		EP 0 429 842 B1	08/28/1996	Europe EPO	A61N 1/30		
34.		EP 1 086 718 A1	03/28/2001	Europe BPO	A61M 37/00		
35.		EP 1 086 719 A1	03/28/2001	Europe Epo	A61M 37/00		
36.		EP 1 088 642 A1	04/04/2001	Europe FPO	B29C 45/37		
37.		EP 1 092 444 A1	04/18/2000	Europe EPO	A61M 5/46>		
38.	( )	WO 94/23777	10/27/1994	PET WIPD	-A61M-5/42		

Examiner:

Date Considered:

PATENT AND TRADEMARK OFFICE O \ P E INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 3 of 6

ATTORNEY DOCKET NO.	SERIAL NO.
6794S-000019/US	09/897,801
APPLICANT	
Pinkerton, Thomas C.	
FILING DATE	GROUP
June 29, 2001	1615

FOREIGN PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No
39.	CA	WO 96/17648	06/13/1996	PCIWIPO	A61N-1/30	
40.		WO 96/37155	11/28/1996	PET WIPO	A61B 17/20	
41.		WO 96/37256	11/28/1996	PCT WIPO	A61N 1/30	
42.		WO 97/21457	06/19/1997	PCT WIPD	A61M-5/20_	
43.		WO 99/43350	09/02/1999	PCT WOOD	A <del>61K 39/39</del> —	
44.		WO 99/64580	12/16/1999	PGT NO	·G12N 15/00	
45.		WO 00/09186	02/24/2000	PGT WOOD	A61M 5/30	
46.		WO 00/67647	11/16/2000	PET WIDO	A61B 17/22	
47.		WO 00/74763 A2	12/14/2000	PGT WIPD	A61M-37/00-	
48.		WO 01/13903 A2	03/01/2001	PET NO PO	A <del>61K-31/00</del> _	
49.		WO 01/37882 A2	05/31/2001	PET WIPD	A61K 49/00	
50.		WO 01/52854 A1	07/26/2001	PCT WIPD	A61K-31/5355-	
51.	NEV	WO 02/11669 A2	02/14/2002	PCT 11,PD	A61K	

OTHE	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)				
Ref. Desig.	Examiner's Initials				
52.	QA-	Agrawal, et al.; <i>Pharmacokinetics, Biodistribution And Stability Of Oligodeoxynucleotides Phosphorothioates In Mice</i> ; <u>Proc. Natl. Acad. Sci. USA</u> 88:7595-7599 (1991)			
53.	CA	Autret, et al.; Comparison Of Pharmacokinetics And Tolerance Of Calcitonine Administered By Intradermal Or Subcutaneous Route; Fundamental Clinical Pharmacology; 3(2):170-171 (1989)			

Examiner:

Date Considered:

PATENT AND TRADEMARK OFFICE NECEMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 4 of 6

ATTORNEY DOCKET No.	SERIAL NO.
6794S-000019/US	09/897,801
APPLICANT	
Pinkerton, Thomas C.	
FILING DATE GROUP	
June 29, 2001	1615

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)				
Ref. Examiner's Desig. Initials				
54. (H)		Benoni, et al.; Distribution Of Ceftazidime In Ascitic Fluid; Antimicrobial Agents and Chemotherapy; 25(6): 760-763, (1984)		
55.		Bocci, et al.; The Lymphatic Route. IV. Pharmacokinetics Of Human Recombinant Interferon α <sub>2</sub> And Natural Interferon β Administered Intradermally In Rabbits; International Journal of Pharmaceuticals; 32:103-110 (1986)		
56.		Bressolle, et al.; A Weibull Distribution Model for Intradermal Administration of Ceftazidime; Journal of Pharmaceutical Sciences; 82(11): 1175-1178 (1993)		
57.		Bronaugh, et al.; Methods For In Vitro Percutaneous Absorption Studies II. Animal Models For Human Skin; Toxicology and Applied Pharmacology; 62:481-488 (1982)		
58.		Burkoth, et al.; Transdermal And Transmucosal Powdered Drug Delivery; Critical Reviews in Therapeutic Drug Carrier Systems; 16(4):331-384 (1999)		
59.		Callen, Jeffrey P., M.D.; Intralesional Corticosteroids; Therapy 4(2): 149-151 (1981)		
60.		Clinical Pharmacology Skin Disease (David R. Bickers, MD, et al. eds., Churchill Livingstone, 1984) pp. 57-90		
61.		Corbo, et al.; Transdermal Controlled Delivery Of Propranolol From A Multilaminate Adhesive Device; Pharmaceutical Research; 6(9):753-758, (1989)		
62.		Cossum, et al.; Disposition Of The <sup>14</sup> C-Labeled Phosphorothioate Oligonucleotide ISIS 2105 After Intravenous Administration To Rats; Journal of Pharmacology and Experimental Therapeutics; 267(3):1181-1190 (1993)		
63.		Cossium, et al.; <i>Pharmacokinetics Of A</i> <sup>14</sup> <i>C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105, After Intradermal Administration In Rats</i> ; <u>Journal of Pharmacology and</u> <u>Experimental Therapeutics</u> ; 269(1):89-94 (1994)		
64.		Crooke, et al.; A Pharmacokinetic Evaluation Of <sup>14</sup> C-Labeled Afovirsen Sodium In Patients With Genital Warts; Clinical Pharmacology and Therapeutics; 56(6):641-646 (1994)		
65.	OB	Firooz, et al., Benefits And Risks Of Intralesional Corticosteroid Injection In The Treatment Of Dermatological Diseases; Clinical and Experimental Dermatology; 20:363-370 (1995)		

			/	/ /	
Examiner:	(6)	Date Considered:	4/	16/03	
			7		

## PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 5 of 6

ATTORNEY DOCKET No.	SERIAL NO.
6794S-000019/US	09/897,801
APPLICANT	
Pinkerton, Thomas C.	
FILING DATE	GROUP
June 29, 2001	1615

	1	NTS (including Author, Title, Date, Pertinent Pages, etc.)
Ref. Desig.	Examiner's Initials	
66.	CH	Goodarzi, et al.; Organ Distribution And Stability Of Phosphorothioated Olgodeoxyribonucleotides In Mice; Biopharmaceutics and Drug Disposition; 13:221-227 (1992)
67.		Haynes, et al.; Ultra-Long-Duration Local Anesthesia Produced By Injection Of Lecithin-Coated Methoxyflurane Microdroplets; Anesthesiology; 63:490-499 (1985)
68.		Henry, et al.; Microfabricated Microneedles: A Novel Approach To Transdermal Drug Delivery; Journal of Pharmaceutical Sciences; 87(8):922-925 (1998)
69.		Jakobson, et al.; Variation In The Blood Concentration Of 1,1,2-Trichloroethane By Percutaneous Absorption And Other Routes Of Administration In The Guinea Pig; Acta Pharmacol. Et Toxicol.; 41:497-506 (1977)
70.		Jarratt, et al.; The Effects Of Intradermal Steroids On The Pituitary-Adrenal Axis And The Skin; Journal of Investigative Dermatology; 62:463-466 (1974)
71.		Kirkpatrick, et al.; Local Anesthetic Efficacy Of Methoxyflurane Microdroplets In Man; Anesthesiology; 67(3A):A254 (1987)
72.		Leroy, et al.; <i>Pharmacokinetics Of Ceftazidime In Normal And Uremic Subjects</i> ; Antimicrobial Agents And Chemotherapy; 25(5):638-642 (1984)
73.		McAllister, et al.; <i>Three-Dimensional Hollow Microneedle And Microtube Arrays</i> ; 10 <sup>th</sup> International Conference on Solid-State Sensors and Actuators – Transducers '99; 2:1098-1101 (1999)
74.		McAllister, et al.; Solid And Hollow Microneedles For Transdermal Protein Delivery; Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.; 26:192-193 (1999)
75.		McGugan, et al.; Adrenal Suppression From Intradermal Triamcinolone; Journal of Investigative Dermatology; 40:271-272 (1963)
76.		Prausnitz, et al.; <i>Microfabricated Needles For Transdermal Protein Delivery</i> ; present at Bioengineering Applications of Microfabrication, November 5, 1999
77.		Scott, et al.; Toxicity Of Interferon; British Medical Journal; 282:1345-1348 (1981)
78.	CH	Supersaxo, et al.; Recombinant Human Interferon Alpha-2a: Delivery To Lymphoid Tissue By Selected Modes Of Application; Pharmaceutical Research; 5(8):472-476 (1988)

/	<b>'</b> )			1	1
Examiner:	lul-	1-1-	Date Considered:	4/16/	03
	- mary -	- <del></del>			

## **PATENT AND TRADEMARK OFFICE** O \ P INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

(Use several sheets if necessary)

Sheet 6 of 6

ATTORNEY DOCKET NO.	SERIAL NO.		
6794S-000019/US	09/897,801		
APPLICANT			
Pinkerton, Thomas C.			
FILING DATE	GROUP	_	
June 29, 2001	1615		

OTHE	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)			
Ref. Desig.	Examiner's Initials			
79.	79. Sutherst, J.R.; Treatment of Pruritus Vulvae By Multiple Intradermal Injections of Alco			
80.		Ward, et al.; Pruritus Vulvae: Treatment By Multiple Intradermal Alcohol Injections; British Journal of Dermatology; 93:201-204 (1975)		
81.		Wu, et al.; Pharmacokinetics Of Methoxyflurane After Its Intra-Dermal Injection As Lecithin-Coated Microdroplets; Journal of Controlled Release 9:1-2 (1989)		
82.	A	Zaynoun, et al.; The Effect Of Intracutaneous Gluccorticoids On Plasma Cortisol Levels;  British Journal of Dermatology; 88:151-156 (1973)		

Examiner:

Date Considered: